Achieve Life Sciences, Inc. Amortization of Debt Issuance Costs
Achieve Life Sciences, Inc. (ACHV) reported Amortization of Debt Issuance Costs of $23.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-11
- Achieve Life Sciences, Inc. amortization of debt issuance costs for the quarter ending 2026-06-30 was $11.00K, a 21.43% decline year-over-year.
- Achieve Life Sciences, Inc. amortization of debt issuance costs for the quarter ending 2026-03-31 was $12.00K, a 14.29% decline year-over-year.
- Achieve Life Sciences, Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $11.00K, a 21.43% decline year-over-year.
- Achieve Life Sciences, Inc. amortization of debt issuance costs for the quarter ending 2025-09-30 was $13.00K.
- Achieve Life Sciences, Inc. amortization of debt issuance costs for fiscal 2025 was $52.00K, a 126.09% increase from fiscal 2024.
- Achieve Life Sciences, Inc. amortization of debt issuance costs for fiscal 2024 was $23.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $23.00K 10-Q · filed 2026-08-11 | $34.00K derived: sum of 3 quarters · filed 2026-08-11 | $47.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $12.00K 10-Q · filed 2026-05-12 | $23.00K derived: sum of 2 quarters · filed 2026-05-12 | $36.00K derived: sum of 3 quarters · filed 2026-05-12 | $50.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $24.00K derived: sum of 2 quarters · filed 2026-03-24 | $38.00K derived: sum of 3 quarters · filed 2026-08-11 | $52.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $27.00K derived: sum of 2 quarters · filed 2026-08-11 | $41.00K 10-Q · filed 2025-11-06 | $55.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $28.00K 10-Q · filed 2026-08-11 | $42.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-12 | $28.00K derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $23.00K 10-K · filed 2026-03-24 | ||
| 2024-09-30 | $9.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |